Validation of a survival prediction tool for metastatic cancer patients receiving palliative radiation
Prospective Validation of a Points Score System Predicting 30-day Survival for Patients With Metastatic Cancer Receiving Palliative Radiation Therapy
Indiana University · NCT05100342
This study is testing a new tool that helps doctors predict how long patients with advanced cancer might live after receiving palliative radiation treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 214 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | Indiana University (other) |
| Drugs / interventions | Radiation |
| Locations | 3 sites (Avon, Indiana and 2 other locations) |
| Trial ID | NCT05100342 on ClinicalTrials.gov |
What this trial studies
This observational study aims to validate a survival prediction tool developed by Lee et al. for patients with metastatic cancer referred to radiation oncology for palliative treatments. Patients will be assigned a survival score based on objective data such as laboratory values and emergency room visits at the time of enrollment. The score ranges from 0 to 20, categorizing patients into low, intermediate, and high-risk groups based on their prognosis. Patient survival and quality of life will be monitored at 30, 90, and 365 days post-enrollment to evaluate the tool's effectiveness.
Who should consider this trial
Good fit: Ideal candidates include adults aged 18 and older with a diagnosis of metastatic cancer referred for palliative radiation therapy.
Not a fit: Patients receiving curative radiation therapy or those unable to participate in follow-up visits may not benefit from this study.
Why it matters
Potential benefit: If successful, this tool could help healthcare providers better predict survival outcomes and tailor palliative care for metastatic cancer patients.
How similar studies have performed: While similar predictive tools have been explored, this specific approach is novel in its application to palliative radiation therapy for metastatic cancer.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. Age ≥ 18 at time of consent 2. Ability to provide written informed consent 3. Cancer diagnosis referred to Radiation Oncology for palliative radiation therapy 4. Patients who either choose to not receive radiation therapy or not recommended to receive radiation therapy will remain eligible 5. Those patients who undergo a course of palliative radiation therapy, it is not the requirement of this study to complete that course of treatment. Those who prematurely end their course of treatment will remain eligible Note: Patients who ultimately either choose to not receive radiation or not recommended to receive radiation will remain eligible Note: Patients who ultimately do not complete prescribed radiation will remain eligible Exclusion Criteria: 1. Patients who are unable to participate in follow up visits per investigator discretion (virtual/phone follow up is permitted) 2. Patients who are receiving definitive/curative course of radiation therapy 3. Patients who self-report as pregnant or nursing
Where this trial is running
Avon, Indiana and 2 other locations
- IU Health West — Avon, Indiana, United States (RECRUITING)
- IU Health North / Schwarz Cancer Center — Carmel, Indiana, United States (RECRUITING)
- Methodist Hospital — Indianapolis, Indiana, United States (RECRUITING)
Study contacts
- Principal investigator: Naoyuki Saito, MD PhD — Indiana University
- Study coordinator: Jessica Anders
- Email: jemlynn@iu.edu
- Phone: (317) 274-0220
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.
Conditions: Metastatic Cancer, palliative radiation, radiation therapy